Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why

Zacks10-08

Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines. In July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 study...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473484691?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae","is_english":true,"pubTime":"2024-10-08 00:27","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2473484691","market":"us","top_or_hot":-1,"title":"Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why","media":"Zacks","content":"<div>\n<p>Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines.\nIn July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 study...</p>\n\n<a href=\"https://finance.yahoo.com/news/sage-therapeutics-stock-down-almost-162700253.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 00:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sage-therapeutics-stock-down-almost-162700253.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines.\nIn July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 study...</p>\n\n<a href=\"https://finance.yahoo.com/news/sage-therapeutics-stock-down-almost-162700253.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4530","symbol_name":"医药外包概念","start_time":0,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-stock-down-almost-162700253.html","article_id":"2473484691","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473484691","pubTimestamp":1728318420,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines.In July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 study, which evaluated its investigational neurology candidate, SAGE-324 as a potential treatment for essential tremor . The study failed to demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with ET.Following the disappointing data, SAGE and BIIB decided to stop further development of SAGE-324 for the ET indication.Last month, Biogen terminated its rights related to SAGE-324. The termination will be effective from Feb. 17, 2025.Following the termination of the deal by BIIB, Sage Therapeutics will obtain full ownership and rights of SAGE-324. The company plans to study SAGE-324 for other indications, if any.Shares of Sage Therapeutics have plunged 39.3% in the past three months against the industry’s growth of 7.9%.Sage Therapeutics has had","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4530":"医药外包概念","BVS":"Bioventus Inc.","BK4023":"应用软件","BK4532":"文艺复兴科技持仓","PD":"PagerDuty, Inc.","BK4144":"石油与天然气的储存和运输","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BIIB":"渤健公司","BK4007":"制药","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4121":"生命科学工具和服务","ANIP":"ANI Pharmaceuticals, Inc.","BK4588":"碎股","BK4198":"医疗保健用品","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","PPD":"PPD, Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SAGE":"Sage Therapeutics","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4561":"索罗斯持仓","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4581":"高盛持仓","ET":"Energy Transfer LP","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4590":"PTP","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","CRL":"查尔斯河"},"translate_title":"Sage Therapeutics股价3个月内下跌近40%：原因如下","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVS":1,"SAGE":1,"PPD":1,"PD":1,"ET":1,"CRL":1,"ANIP":1,"BIIB":1},"content_text":"Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines.\nIn July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 study, which evaluated its investigational neurology candidate, SAGE-324 as a potential treatment for essential tremor (ET). The study failed to demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with ET.\nFollowing the disappointing data, SAGE and BIIB decided to stop further development of SAGE-324 for the ET indication.\nLast month, Biogen terminated its rights related to SAGE-324. The termination will be effective from Feb. 17, 2025.\nFollowing the termination of the deal by BIIB, Sage Therapeutics will obtain full ownership and rights of SAGE-324. The company plans to study SAGE-324 for other indications, if any.\nShares of Sage Therapeutics have plunged 39.3% in the past three months against the industry’s growth of 7.9%.\nImage Source: Zacks Investment Research\nThe disappointing data on SAGE-324 and the subsequent termination of the deal by BIIB could have been the reasons for the stock’s decline during the said time.\nPipeline Setbacks a Concern for SAGE\nSage Therapeutics has had its share of pipeline setbacks that has remained a constant niggle for the company in recent quarters.\nIn April 2024, SAGE reported that the phase II PRECEDENT study on dalzanemdor in Parkinson’s disease (PD) failed to achieve its primary endpoint. Based on this outcome, management decided not to pursue the development of the candidate in PD indication.\nWe remind investors that the FDA issued a complete response letter (CRL) for the new drug application (NDA) for zuranolone for treating adults with major depressive disorder in August 2023. Per the FDA, the data supporting the NDA filing did not provide substantial evidence of effectiveness to support a potential approval. FDA recommended conducting additional clinical studies. Such setbacks do not bode well for the company.\nSAGE currently markets the depression drug Zurzuvae (zuranolone) in partnership with Biogen.\nZurzuvae, the first and only oral treatment indicated for adults with postpartum depression (PPD), was approved by the FDA in August 2023 and commercially launched in December.\n\nSage Therapeutics, Inc. Price\n  \nSage Therapeutics, Inc. price | Sage Therapeutics, Inc. Quote\n\nSAGE's Zacks Rank & Stocks to Consider\nSage Therapeutics currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the drug/biotech sector are ANI Pharmaceuticals, Inc. ANIP and Bioventus Inc. BVS, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 3%.\nANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.\nIn the past 60 days, estimates for Bioventus’ 2024 earnings per share have increased from 27 cents to 40 cents. Earnings per share estimates for 2025 have improved from 43 cents to 45 cents. Year to date, shares of BVS have risen 41.8%.\nBVS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 102.86%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBiogen Inc. (BIIB) : Free Stock Analysis Report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nSage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report\nBioventus Inc. (BVS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473484691"}